巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Opthea Limited

    OPT
    7.180
    0.000
    0.00%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Opthea Limited - 延遲價格・最後更新於 10/08 9:30
    最高位
    --
    最低位
    --
    開市價
    --
    前收市價
    7.180
    成交量(千)
    --
    成交額(百萬)
    --
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    315.87
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    8.720 - 4.734
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Opthea Limited
    證券代碼
    OPT.US
    所屬板塊
    Biotechnology
    公司業務
    Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
    發行量
    43992410
    公司總部
    650 Chapel Street, Level 4, Suite 0403
    公司網址
    http://www.opthea.com
    公司電話
    +61 398260399
    暫無內容

    關於

    Opthea Limited(OPT.US)所屬的行業板塊為Biotechnology。
    Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
    詳細公司背景可參考: http://www.opthea.com